adebrelimab + chidamide + gemcitabine

Adebrelimab + chidamide + gemcitabine is an investigational combination therapy being evaluated for the treatment of pancreatic cancer. This regimen combines **adebrelimab**, a humanized IgG4 monoclonal antibody targeting programmed cell death-ligand 1 (PD-L1); **chidamide** (tucidinostat), an oral subtype-selective histone deacetylase (HDAC) inhibitor; and **gemcitabine**, a standard-of-care nucleoside analog chemotherapy. The combination aims to leverage the epigenetic modulating effects of chidamide—which can enhance tumor immunogenicity and reverse immune evasion—to sensitize the tumor microenvironment to PD-L1 blockade and cytotoxic chemotherapy. Clinical research, including studies led by the First Affiliated Hospital of Soochow University, typically explores this triplet (often alongside nab-paclitaxel) as a first-line or neoadjuvant treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma.

Brand names

Adely